The regulator has made a decision. IMO it is unlikely they didn’t think about it or look at the evidence. They obviously had concerns about the product. This was clear previously as well. Although there is always a chance, unlikely the decision will be reversed. Some hope for provisional approval with undertaking that a further study is done after. More likely the further study will be required first. (all IMO)
No chance Scotty from marketing will have any sway at all. It is not a political process despite many posts believing this is the reason for non approval. A good conspiracy about why the umpire cheated us may make you feel better, but won’t change the facts.
Sad for such a promising Australian company. Will likely take a fair bit of coin and time to firm up the evidence. Hold on and see how it goes I suppose.
- Forums
- ASX - By Stock
- MSB to dispute FDA finding in Type A meeting
The regulator has made a decision. IMO it is unlikely they...
-
-
- There are more pages in this discussion • 922 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B |
Open | High | Low | Value | Volume |
$1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 24758 | $1.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.49 | 73626 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10033 | 1.485 |
4 | 53700 | 1.480 |
1 | 770 | 1.475 |
3 | 62048 | 1.460 |
1 | 50000 | 1.455 |
Price($) | Vol. | No. |
---|---|---|
1.490 | 21995 | 1 |
1.505 | 24000 | 1 |
1.510 | 13666 | 2 |
1.515 | 99798 | 1 |
1.520 | 27250 | 3 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
MSB (ASX) Chart |